Med24
metabolic-therapy 28. 10. 2026 • 2 min read • Diabetes, obesity & metabolism (PubMed)

Tirzepatide Use Resulted in Clinically Meaningful Weight Reduction in Individuals With Obesity or Overweight: 12-Month Real-World Results.

AIMS: This study assessed the real-world effectiveness of tirzepatide in commercially insured individuals without diabetes, eligible for obesity medications (OMs), including glucagon like-peptide-1 receptor agonist (GLP-1 RA)-naïve individuals (i.e., no GLP-1 RA prescription during the 12-month pre-index period) and...

Knowledge and self-reported practice of laboratory biosafety among medical laboratory professionals in selected public and private hospitals in Mogadishu, Somalia: a cross-sectional study

This study examined the effectiveness of tirzepatide in commercially insured individuals without diabetes who were eligible for obesity medications. The research utilized data from Optum’s Market Clarity database, focusing on adults with continuous enrollment and documented tirzepatide prescriptions between November 2023 and March 2024. The study included two cohorts: individuals who had not previously used glucagon like-peptide-1 receptor agonists (GLP-1 RA) and those who had.

Data was collected from 353 individuals, comprising 230 GLP-1 RA-naïve individuals and 123 GLP-1 RA-experienced individuals, who remained on tirzepatide for 12 months. Baseline assessments revealed that a majority of participants had at least one obesity-related complication, frequently dyslipidemia, hypertension, and prediabetes.

At the 12-month mark, the GLP-1 RA-naïve cohort demonstrated a mean weight reduction of 19.3%, while the GLP-1 RA-experienced cohort achieved a mean weight reduction of 13.1%.

Sponsored content

These real-world findings indicated clinically meaningful weight reduction with persistent tirzepatide use, mirroring outcomes observed in clinical trials, across both GLP-1 RA-naïve and experienced populations.

Original Scientific Source
Diabetes, obesity & metabolism (PubMed)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.
metabolic-therapy

Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.

Insulin resistance is an important metabolic derangement contributing to the pathogenesis of type 2 diabetes, obesity, metabolic syndrome, and other chronic diseases, underlining the requirement for techniques that enable in vivo analysis of tissue-specific glucose metabolism. 18F-fluorodeoxyglucose positron emission...

10. 11. 2026 Read article →
Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.
metabolic-therapy

Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.

BACKGROUND: Although body mass index (BMI) is widely used to assess obesity-related health risks, it may fail to detect individuals with normal weight who present with significant cardiometabolic abnormalities. This phenotype, often overlooked in clinical practice, is associated with increased risk of cardiovascular...

30. 10. 2026 Read article →
Advertisement